GLP-1 RA initiators had 57% lower cardiomyopathy risk vs metformin (HR 0.43, p<0.001) over up to 18.5 years in 10,382 matched cancer+T2D patients exposed to cardiotoxic treatments.
57% less cardiomyopathyCancer patients on GLP-1 drugs had less than half the heart damage risk of those on metformin after cardiotoxic cancer treatment
What the researchers found
GLP-1 RA vs metformin: cardiomyopathy risk 0.31% vs 0.94%; HR 0.43 (0.24-0.76, p<0.001); consistent across high-risk subgroups; up to 18.5 years follow-up.
Why it matters
Cancer patients face cardiac damage from treatment. A 57% reduction in cardiomyopathy from a widely available drug could prevent heart failure in cancer survivors.
How the study worked
Target trial emulation using global EHR database, 10,382 propensity-matched cancer+T2D patients, comparing GLP-1 RA vs metformin initiation (2006-2024), primary outcome: incident cardiomyopathy.
What this study cannot tell us
Observational. Metformin itself has cardioprotective properties, so the comparison may underestimate GLP-1 benefit vs no treatment. Cancer types not specified.
How to read the evidence
Target trial emulation with propensity matching. Long follow-up (up to 18.5 years). Strong signal.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs may protect the heart during cancer treatment, potentially becoming part of cardio-oncology prevention protocols.
Questions still open
- Should GLP-1 drugs be started before cardiotoxic cancer therapy?
- What mechanism explains GLP-1 cardioprotection during cancer treatment?
- Would a dedicated cardio-oncology RCT of GLP-1 drugs be feasible?
Common questions
Can GLP-1 drugs protect the heart during cancer treatment?
Should all cancer patients take GLP-1 drugs?
Read the original research
GLP-1 RA initiation versus metformin and risk of cardiomyopathy in patients with cancer and diabetes treated with chemotherapy, radiation, or immunotherapy: a target trial emulation.
Diabetes research and clinical practice, 233, 113119
Citation
Hernández-Pérez, Jesús Gibran; Abdelgadir, Omer; Hussain, Maryam R; Almandoz, Jaime P; Barcenas, Carlos H; Shah, Amil; Cowell, Lindsay G; Messiah, Sarah E; Lopez, David S. (2026). GLP-1 RA initiation versus metformin and risk of cardiomyopathy in patients with cancer and diabetes treated with chemotherapy, radiation, or immunotherapy: a target trial emulation.. Diabetes research and clinical practice, 233, 113119. https://doi.org/10.1016/j.diabres.2026.113119